A randomized phase 2 study of the antibody-drug conjugate CDX-011
This is one of the hottest technologies that oncologists across the World are watching. The target specific delivery of drug to tumor is the treatment of the future. Side effects are minimized and a much higher success profile are the results of CLDX's Antibody Drug Conjugate products. This platform and intellectual value adds hugely to the eventual negotiating price, (whether that be partnership or buyout).